ABOUT US

ESG

We are committed to being a socially responsible and sustainable company
by listening to our stakeholders’ voices and understanding what their expectations are.

Samsung Bioepis is committed to pursuing sustainability management with a focus on ESG(Environment, Social, and Governance). We plan to share our yearly achievements and activities transparently through our annual report, and enhance the effectiveness of our sustainability management by gathering our various stakeholders' opinions and reflecting them.

  • Building a Sustainable Supply Chain

    APPROACH
    Samsung Bioepis selects suppliers according to strict criteria aimed at building and operating a responsible supply chain, and they are managed through a transparent registration system. For CMOs in particular, we carefully select companies that have obtained international standard (ISO) certification for their environmental management, energy management, and occupational health and safety management systems, verifying that they systematically practice environmental and safety management. Going a step further, we are reviewing the introduction of a policy for the preferential use of eco-friendly transportation as a way of governing the environmental impact of our supply chain. We are also discussing the use of additional ESG evaluation items in our processes for supplier selection, regular evaluations, and contract renewal.

    PERFORMANCE

    • Distribution of 2016 Supplier Code of Conduct
    • CMO ISO Certifications Obtation Rate
    • Environmental Management System  80%
      ISO 14001
      Environmental Management System
    • Occupational Health and Management System 70%
      ISO 45001
      Occupational Health and Management System
    • Energy Management System 40%
      ISO 50001
      Energy Management System

    Key Suppliers in the Samsung Bioepis Supply Chain

    삼성바이오에피스 공급망 핵심 협력사 이미지

    Our partners include raw material suppliers, contract research organizations, contract manufacturing organizations (CMOs), logistics companies (transport, storage), and commercialization partners. Partners from whom annual purchases exceed 1 billion KRW, including CMOs (DS/DP/FDP), logistics companies and raw material suppliers, are designated as key suppliers, and to these partners we apply active selection and management processes.

    Supplier Evaluations

    Supplier qualification process
    • 최초평가 아이콘
      Initial
      qualification
      Evaluates the
      appropriateness of
      new suppliers
    • 정기 평가 아이콘
      Regular
      qualification
      Conducts a regular
      qualification for
      qualified supplier
    • For-cause 평가 아이콘
      For-cause
      audit
      Evaluates a supplier
      “for-cause,” i.e. when a
      potentially serious issues
      related to quality or complaint
      of our product is raised

    When sourcing from CMOs for clinical or commercial purposes, we conduct supplier evaluations to minimize risk in these relationships while boosting the competitiveness of our partners. Led by the Quality Team, supplier qualification covers not only quality management systems, but also facilities, equipment, manufacturing management systems and more. We meet regularly with key partners such as CMOs and logistics companies to share the results of these evaluations and discuss steps for improvement. Going forward, we plan to add ESG evaluation items to the processes for supplier selection, and contract renewal.

  • Strengthening Product Responsibility and Safety

    APPROACH
    By increasing market competition, biosimilars have become an important lever for the innovation of next generation biologics. While our focus remains on the development of high-quality biosimilars, we are now taking our first steps into novel biologic development. We are also looking to enhance the patient experience, including the development of ergonomic autoinjector devices and extended storage conditions for our products.

    PERFORMANCE

    • Product development
      Biosimilars Biosimilars
      6/10
      Six products approved
      In ten pipelines(As of 2021)
      Novel biologics Novel biologics
      1
      One in development(As of 2021)
    • R&D Investment
      investment amount
      180.6
      Billion KRW(As of December 2020)
  • Strengthening Environmental Management

    APPROACH
    At Samsung Bioepis, we have established environmental management principles and systems adhered to the green management philosophy, which we are practicing across the company. As an R&D company with low energy consumption, we are not subject to targets for Greenhouse Gas (GHG) emissions and energy consumption. Nonetheless, we are continuing our proactive efforts to save energy and reduce emissions. Furthermore, we have put in place a management system for water resources, waste, air pollutants and hazardous chemicals, and we are introducing eco-friendly packaging materials as part of building a circular economy and enhancing resource efficiency.

    PERFORMANCE

    • Reducing greenhouse gas emissions
      Using high-efficiency Equipment
      Using high-efficiency Equipment
      LED lighting (90% of all lighting),
      high-efficiency pumps,
      high-efficiency heat pumps
      Reducing energy consumption
      Reducing energy consumption
      Lights/HVAC turned off,
      Outside of work hours, cooling control system with inverters
    • Enhancing resource efficiency
      Developing eco-friendly  packaging
      Developing eco-friendly packaging
      Package size reduction,
      use of paper trays,
      no plastic coating
      친환경 운송 추진
      Promoting eco-friendly shipping
      No PVC wrapping,
      shipper boxes made of
      recycled paper
지속가능경영보고서 이미지
Sustainability Report
  • ESH (Environmental, Safety and Health) Policy

    Samsung Bioepis prioritizes securing the safety and health of customers, employees, and community while we comply with rule & process to prevent accidents and to protect environment, and practice compliance management.

    Recognizing that safety, health and environmental protection are of the utmost value and should not be compromised in any circumstances for corporate sustainability management, Samsung Bioepis will :

    Encourage executives to continuously demonstrate leadership and commitment to ESH management.

    Communicate the values and objectives of ESH management to ensure that they are put into action company-wide with all employees and cooperative firms (CMO, CRO, Marketing Partner, cooperative firms for infra management and so on).

    Ensure all employees and cooperative firms actively comply with the rule & process to prevent accidents and to protect environment.

    Ensure elimination of hazards, and reduction of safety and health risks prior to any work and create safe, healthy and pleasant working environment and make effort for continuous improvement.

    Continue to put in best efforts to minimize the release of GHG